MARKET

ATHE

ATHE

Alterity Therapeutics Ltd
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.6395
-0.0705
-9.93%
Closed 16:00 04/03 EDT
OPEN
0.7000
PREV CLOSE
0.7100
HIGH
0.7000
LOW
0.6300
VOLUME
13.95K
TURNOVER
--
52 WEEK HIGH
2.550
52 WEEK LOW
0.2800
MARKET CAP
9.30M
P/E (TTM)
-0.9149
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ATHE stock price target is 4.000 with a high estimate of 4.000 and a low estimate of 4.000.

EPS

ATHE News

More
  • The Daily Biotech Pulse: Trevana Pain Drug Resubmission Accepted For Review, Can-Fite To Explore Treatment For COVID-19
  • Benzinga · 03/05 13:14
  • Imagine Owning Alterity Therapeutics (ASX:ATH) And Trying To Stomach The 86% Share Price Drop
  • Simply Wall St. · 02/22 00:15
  • The Daily Biotech Pulse: PhaseBio To Buy Hypertension Asset, Stemline Falls On Q4 Pre-Announcement, FDA Panel To Review Nektar's Opioid Drug
  • Benzinga · 01/14 12:55
  • The Daily Biotech Pulse: Acorda Surges As Point72 Hikes Stake, Novan Sinks On Failed Study, Illumina-Pac Bio Terminate Merger
  • Benzinga · 01/03 12:55

Industry

Biotechnology & Medical Research
-0.50%
Pharmaceuticals & Medical Research
-0.22%

Hot Stocks

Symbol
Price
%Change

About ATHE

Alterity Therapeutics Limited, formerly Prana Biotechnology Limited, is a development-stage medical biotechnology company. The Company is engaged in the research and development of therapeutic drugs designed to treat the underlying cause of degeneration of the brain focusing on Alzheimer's disease, Huntington disease, Parkinson's disease and other neurological disorders. The Company's lead product candidates are PBT2 and PBT434. The Company's lead drug candidate PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. The Company also has advanced a drug candidate for Parkinson's disease and other movement disorders (PBT434) and brain cancer (PBT519), which are in pre-clinical toxicology testing. Its other applications for its therapies include certain cancers, age-related macular degeneration, Motor Neuron disease, Creutzfeldt-Jakob disease (the human variant of Mad Cow disease), and a range of orphan neurodegenerative disorders.
More

Webull offers kinds of Alterity Therapeutics Ltd (ADR) stock information, including NASDAQ:ATHE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATHE stock news, and many more online research tools to help you make informed decisions.